Palvella Therapeutics (PVLA) Competitors $54.14 +0.63 (+1.18%) As of 09/4/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. OGN, DNLI, IBRX, CNTA, AGIO, IDYA, OCUL, HRMY, RXRX, and IRONShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Organon & Co. (OGN), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Centessa Pharmaceuticals (CNTA), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Harmony Biosciences (HRMY), Recursion Pharmaceuticals (RXRX), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Its Competitors Organon & Co. Denali Therapeutics ImmunityBio Centessa Pharmaceuticals Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Recursion Pharmaceuticals Disc Medicine Palvella Therapeutics (NASDAQ:PVLA) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Is PVLA or OGN more profitable? Organon & Co. has a net margin of 11.15% compared to Palvella Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 163.88% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -62.30% -43.34% Organon & Co. 11.15%163.88%6.99% Do analysts rate PVLA or OGN? Palvella Therapeutics presently has a consensus target price of $58.50, indicating a potential upside of 8.05%. Organon & Co. has a consensus target price of $18.00, indicating a potential upside of 86.14%. Given Organon & Co.'s higher possible upside, analysts clearly believe Organon & Co. is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Organon & Co. 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has better earnings and valuation, PVLA or OGN? Organon & Co. has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M13.99-$17.43M-$12.10-4.47Organon & Co.$6.40B0.39$864M$2.693.59 Do institutionals and insiders believe in PVLA or OGN? 40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by insiders. Comparatively, 2.0% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, PVLA or OGN? Palvella Therapeutics has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Does the media favor PVLA or OGN? In the previous week, Palvella Therapeutics and Palvella Therapeutics both had 6 articles in the media. Organon & Co.'s average media sentiment score of 1.17 beat Palvella Therapeutics' score of 1.03 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryOrganon & Co. beats Palvella Therapeutics on 11 of the 15 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$591.80M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-4.4720.8975.6126.43Price / Sales13.99458.96550.93119.09Price / CashN/A44.5237.0558.92Price / Book9.709.9311.246.06Net Income-$17.43M-$53.38M$3.29B$266.28M7 Day Performance-0.02%0.63%0.20%-0.33%1 Month Performance44.30%6.31%6.31%3.43%1 Year PerformanceN/A11.63%56.09%23.10% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics2.0873 of 5 stars$54.14+1.2%$58.50+8.1%N/A$591.80M$42.81M-4.47N/APositive NewsOGNOrganon & Co.4.8165 of 5 stars$9.21+1.5%$18.00+95.5%-56.5%$2.36B$6.40B3.424,000Positive NewsDNLIDenali Therapeutics4.3501 of 5 stars$15.60+0.3%$33.62+115.5%-41.2%$2.27B$330.53M-5.57430Positive NewsIBRXImmunityBio2.8468 of 5 stars$2.34-1.7%$10.75+359.4%-35.4%$2.25B$14.74M-4.87590CNTACentessa Pharmaceuticals3.5292 of 5 stars$16.65-0.8%$28.10+68.8%+7.9%$2.25B$6.85M-9.30200News CoveragePositive NewsAnalyst ForecastAnalyst RevisionAGIOAgios Pharmaceuticals4.3358 of 5 stars$39.27+2.1%$56.33+43.5%-19.3%$2.23B$36.50M3.57390Trending NewsAnalyst ForecastOptions VolumeGap DownIDYAIDEAYA Biosciences4.4258 of 5 stars$25.00+0.6%$47.10+88.4%-32.9%$2.18B$7M-6.6080Trending NewsAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.6349 of 5 stars$12.32flat$17.20+39.6%+50.7%$2.14B$63.72M-9.63230News CoveragePositive NewsHRMYHarmony Biosciences4.4102 of 5 stars$38.05+2.4%$51.00+34.0%+0.7%$2.14B$714.73M12.27200News CoveragePositive NewsRXRXRecursion Pharmaceuticals2.3854 of 5 stars$4.89+1.2%$7.00+43.1%-25.9%$2.10B$58.84M-2.75400Positive NewsIRONDisc Medicine3.3116 of 5 stars$59.95+0.3%$98.30+64.0%+22.2%$2.08BN/A-13.4130News CoveragePositive News Related Companies and Tools Related Companies OGN Competitors DNLI Competitors IBRX Competitors CNTA Competitors AGIO Competitors IDYA Competitors OCUL Competitors HRMY Competitors RXRX Competitors IRON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVLA Stock Alerts